The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia

(COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

The present invention relates to an antiviral application of nucleoside analogs. Specifically, the present invention relates to uses of nucleoside analogs and a pharmaceutical composition thereof as: (a) inhibitors for inhibiting the replication of coronaviruses, influenza viruses, respiratory syncytial viruses, flaviviridae viruses, filoviridae viruses and/or porcine epidemic diarrhea virus (PEDV); and/or (b) medicines for treating and/or preventing and mitigating diseases caused by coronavirus, influenza virus, respiratory syncytial virus, flaviviridae virus, filoviridae virus and/or porcine epidemic diarrhea virus (PEDV) infections. The nucleoside analogs according to the invention may treat and/or prevent and mitigate respiratory infection, pneumonia

(COVID-19) and other related diseases caused by 2019 novel coronavirus infection.

A compound of formula (I)

##STR00001## wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R.sub.3 are in vicinal position (if m=0 then R.sub.3 is in position 2′, and if m=1 then R.sub.3 is on position 1′); R is ethyl or vinyl; R.sub.1 is hydrogen or (C.sub.1-6)alkyl, R.sub.2 is hydrogen or (C.sub.3-6)cycloalkyl, or unsubstituted (C.sub.1-6)alkyl, or (C.sub.1-6)alkyl substituted by one or more of hydroxy; preferably one or two, methoxy, halogen, (C.sub.3-6)cycloalkyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatom e. g. selected from N or O, or R.sub.1 is hydroxy and R.sub.2 is formyl; R.sub.3 is OH, OR.sub.4, a halogen atom, or R.sub.3 is bound to 2′ and represents —O—(CH.sub.2).sub.p—O— with p is 2 or 3; R.sub.4 is unsubstituted (C.sub.1-6)alkyl or (C.sub.3-6)cycloalkyl, or a pharmaceutically acceptable salt, solvate, prodrug or metabolite thereof for the specific use in the treatment or prevention of a disease mediated by a virus.

A compound of formula (I)

##STR00001## wherein n is 0 to 4; m is 0 or 1 with the proviso that the sulphur atom and R.sub.3 are in vicinal position (if m=0 then R.sub.3 is in position 2′, and if m=1 then R.sub.3 is on position 1′); R is ethyl or vinyl; R.sub.1 is hydrogen or (C.sub.1-6)alkyl, R.sub.2 is hydrogen or (C.sub.3-6)cycloalkyl, or unsubstituted (C.sub.1-6)alkyl, or (C.sub.1-6)alkyl substituted by one or more of hydroxy; preferably one or two, methoxy, halogen, (C.sub.3-6)cycloalkyl, or R.sub.1 and R.sub.2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatom e. g. selected from N or O, or R.sub.1 is hydroxy and R.sub.2 is formyl; R.sub.3 is OH, OR.sub.4, a halogen atom, or R.sub.3 is bound to 2′ and represents —O—(CH.sub.2).sub.p—O— with p is 2 or 3; R.sub.4 is unsubstituted (C.sub.1-6)alkyl or (C.sub.3-6)cycloalkyl, or a pharmaceutically acceptable salt, solvate, prodrug or metabolite thereof for the specific use in the treatment or prevention of a disease mediated by a virus.

Disclosed herein are new therapeutic methods comprising administering compounds that can stabilize HIF and inhibit HIF prolyl hydroxylase (HIF-PH). In particular, methods described herein can be useful for treating/preventing a disease or condition in patients in need thereof, such as a patient having a viral infection such as a respiratory and/or pulmonary viral infection (e.g., an infection such as COVID-19 or a coronavirus infection). Methods described herein can also be useful for treating/preventing organ injury (e.g. organ injury that occurs concurrently or as a result of an infection). For example, methods described herein can be useful for treating or preventing acute lung injury, acute respiratory distress syndrome (ARDS), cardiovascular injury, injury to the liver, kidney diseases, and/or multi-organ failure.

Described herein are antiviral peptides, polynucleotides encoding the peptides, and compositions containing the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and compositions for treating or inhibiting a viral infection or one or more symptoms of a viral infection.

Described herein are antiviral peptides, polynucleotides encoding the peptides, and compositions containing the peptides. Furthermore, described herein are methods for using the peptides, polynucleotides, and compositions for treating or inhibiting a viral infection or one or more symptoms of a viral infection.

Provided are immunogenic compositions comprising a secreted fusion protein, wherein the secreted fusion protein comprises a soluble influenza or rabies viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. Also provided are uses of the immunogenic compositions for generating an immune response against influenza or rabies infection and in a vaccine composition. Also provided are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.

Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.

Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.